. This important antiviral class inhibits viral polymerases after cellular uptake and conversion to their diphosphates, bypassing the first phosphorylation which is required for conventional nucleoside antivirals. Small chemical alterations in the acyclic side chain lead to marked differences in antiviral activity and the spectrum of activity of acyclic nucleoside phosphonates against various classes of viral agents. We synthesized a new class of acyclic nucleoside phosphonates based on a 5-phosphono-pent-2-en-1-yl base motif in which the oxygen heteroatom usually present in acyclic nucleoside phosphonates has been replaced with a double bond. Since the intrinsic phosphonate moiety leads to low oral bioavailability and impaired cellular penetration, we also prepared the hexadecyloxypropyl esters of the 5-phosphono-pent-2-en-1-yl nucleosides. Our earlier work showed that this markedly increases antiviral activity and oral bioavailability.
INTRODUCTION
The acyclic nucleoside phosphonates (ANPs) are an important class of antiviral drugs that are approved for treatment of viral infections, including infections with cytomegalovirus (cidofovir, Vistide ® ), hepatitis B virus (adefovir dipivoxil, Hepsera ® ) and HIV-1 (tenofovir disoproxil fumarate, Viread ® ) (11, 12) . To show antiviral activity, ANPs must 1) undergo intracellular activation to the diphosphate, 2) compete with endogenous deoxynucleotide triphosphates for binding to the viral polymerase, and 3) incorporate into the nascent DNA and 4) terminate viral replication. ANPs possess an enzymatically stable phosphonomethyl ether which, unlike conventional nucleoside antivirals, makes them independent of the first intracellular phosphorylation step.
In general, antiviral nucleosides and ANPs consist of a base moiety and a carbohydrate mimic. Structural features of the carbohydrate mimic influence the ability of the nucleoside analog to participate in the antiviral mechanism. For example, the 5′-triphosphates of stavudine (d4T, 2′,3′-didehydro-3′-deoxythymidine) and abacavir (Ziagen, (1S,4R)-cis-4-[2-amino-6-chloro-9H-purin-9-yl]-2-cyclopentene-1-methanol), are potent inhibitors of HIV replication, and the presence of a double bond in the sugar moiety appears to play a role in binding to the HIV reverse transcriptase (9) . Likewise, potent antiviral activity is found in ANPs possessing a phosphonomethoxyethyl side chain; changes in the acyclic side chain or in the nucleoside base modulate activity and the antiviral spectrum against various virus classes (15).
We now describe the antiviral evaluation of a new series of acyclic nucleoside phosphonate analogs, the 5-phosphonopent-2-en-yl (PPen) nucleosides, which 
MATERIALS AND METHODS

Synthesis of PPen Nucleosides
The details of the syntheses of the PPen nucleosides and their hexadecyloxypropyl esters will be published elsewhere. Proof of structure and purity (>98%) of all compounds was confirmed by 1 H and 31 P nuclear magnetic resonance, electrospray ionization mass spectrometry and thin layer chromatography (silica gel plates with visualization by UV light, Phospray (Supelco, Bellefonte, PA) and charring at 400 °C).
Cells and Viruses
Human foreskin fibroblast (HFF) cells were prepared as primary cultures and used in the CMV, VZV, VV and CV assays. CMV strain AD-169 and VZV strain Ellen were propagated using standard virological techniques as reported previously (38) . VV strain Copenhagen and CV strain Brighton were kindly provided by John W. Huggins (4, 19) .
Plaque reduction assays in HFF cells
The plaque reduction assays for CMV, VV, CV and VZV were performed as described previously (5, 37, 38) and standard methods were used to determine the compound concentration required to reduce plaque formation by 50% (EC 50 ).
Enzyme-Linked Immunosorbent Assay for EBV EBV assays were done as described previously (38) . ELISA was performed on cells fixed with 95% EtOH/acetic acid, rinsed with PBS, incubated with a monoclonal antibody to EBV VCA (Chemicon, Temecula, CA) followed by an incubation with horseradish peroxidase labeled goat anti-mouse IgG1 (Southern Biotechnology, Birmingham, AL) and the EC 50 and CC 50 values determined (38) . . DNA reduction antiviral assays for activity against HSV-1 in vitro.
The antiviral activities were determined against HSV-1 by DNA reduction with MRC-5 human lung fibroblast cells using HSV-1 DNA probes as described previously (19) . The assays were done and the CC 50 values were determined as described previously (4, 5, 36, 37, 38) .
HBV Antiviral Analysis.
Confluent cultures of 2.2.15 cells were maintained on 96-well flat-bottomed tissue culture plates in RPMI1640 medium with 2% FBS as previously described (26) .
Cultures were treated with nine consecutive daily doses of the test compounds (six for each test concentration on two replicate plates). The culture medium was changed every day with medium containing the indicated concentration of the test compounds.
HBV DNA levels were assessed by quantitative blot hybridization 24 h after the last treatment. Cytotoxicity was assessed by uptake of neutral red dye and semiquantitative analysis of the absorbance of internalized dye at 510 nM (A 510 ) 24h following the last treatment (three cultures per test concentration) (26) . Activity against lamivudineresistant (2) and adefovir-resistant (3) HBV mutants was determined in a 5-day assay using a transient transfection method in Huh7 cells and cytotoxicity determined as previously described (21) . presence of threefold serial drug dilutions (three wells per dilution) as previously described (13). The antiviral activity of each compound is expressed as the EC 50 , which is the concentration required to inhibit p24 antigen production by 50%.
MT-2 Cytotoxicity
Cytotoxicity was assessed in rapidly dividing MT-2 cells incubated with drug for 72 h and harvested. Flow count beads (Beckman Coulter, Miami, FL) were added to the cell suspension followed by propidium iodide staining and analysis using an Epics Elite flow cytometer (Beckman Coulter). The 50% cytotoxic concentration (CC 50 ) was calculated from the cell counts and viability (13).
RESULTS
The PPen nucleosides were tested against CMV, HSV, VV, CV, VZV, and EBV (Table 1 ). The unmodified PPen nucleosides were inactive, except for PPen-G which showed low but measurable activity against CMV and VZV. However, when esterified with the hexadecyloxypropyl group, substantial activity was noted in most cases. HDP- In MT-2 cells infected with HIV-1, significant activity was noted only with HDPPPen-C (EC 50 2.5 µM) and HDP-PPen-T (EC 50 1.0 µM). However, there was little antiviral selectivity as the cytotoxic concentration 50% for these two compounds was 3.3 and 1.3 µM, respectively (data not shown).
We also evaluated the HDP-PPen nucleosides against HBV in 2.2.15 cells ( Table   2 ). As noted with the DNA viruses, the PPen nucleosides were without activity against HBV but their HDP esters had antiviral activity with EC 50 values ranging from 1.8 to 3.9 µM. Although the HDP esters were more cytotoxic, their selectivity indexes were substantial, ranging from 61 to >417. Neither PPen-U nor its HDP ester showed antiviral activity against HBV.
The active compounds were also evaluated against a panel of drug resistant hepatitis B viruses (Table 3 In our own efforts to identify selective virus inhibitors, we prepared a novel family of nucleotide analogs using a phosphonopentenyl group as the acyclic sugar moiety.
The general structure of the new compounds, 5-phosphonopent 2-en-1-yl nucleosides (PPen Ns) is shown in Figure 1 . The phosphonopentenyl side chain design was chosen so that the resulting analogs would resemble the corresponding portion of 2′,3′-didehydro-2′,3′-dideoxynucleosides such as stavudine, d4A and abacavir, nucleosides with potent anti-HIV activity. Choo et al. (9) found previously that the 2′,3′ double bond (Tables 1 and 2 ).
A C C E P T E D
We have observed that ANPs frequently fail to exhibit biological activity in vitro because the double negative charge associated with the phosphonate group impairs transport of drug through the cell membrane (1) . In earlier work we prepared ANP's modified with lipophilic groups to create mimics of lysophosphatidylcholine, a dietary lipid which is absorbed intact from the gastrointestinal tract and readily metabolized in cells. We showed that cidofovir modified by esterification with a hexadecyloxypropyl group (HDP-CDV) enters cells rapidly and is metabolized to give levels of CDVdiphosphate, the active metabolite, that are 100-fold higher relative to unmodified CDV (1) . The in vitro activity of (S)-HPMPA was also enhanced using this strategy (5), and some weakly active ANP's displayed significant activity after lipid modification (33, 35) .
Esterification with alkoxyalkyl groups also makes ANPs orally bioavailable (10) and
on October 15, 2017 by guest http://aac.asm.org/ Downloaded from orally effective against lethal poxvirus infections (7,31). This was the rationale for the synthesis of the hexadecyloxypropyl esters of the PPen nucleosides. We evaluated them for antiviral effects against various viruses and found that several now showed significant activity ( Table 1 ). The broadest antiviral activity was found in the guanine analog, HDP-PPen-G, which had EC 50 s below 12 µM for all viruses except HIV-1 and EBV. HDP-PPen-A was a slightly stronger inhibitor of HBV (EC 50 1.5 µM) and showed substantial activity against EBV (EC 50 0.1 µM). Against HIV-1, only the two pyrimidine analogs HDP-PPen-C and HDP-PPen-T showed significant activity but exhibited no antiviral selectivity. As expected, HDP-PPen-U was inactive in all the antiviral assays (VZV and EBV not assayed).
Since four of the five HDP-PPen nucleoside compounds inhibited HBV replication, and our previous work demonstrated that alkoxyalkyl esters of nucleoside phosphates and phosphonates are targeted to the liver (10, 17, 18) , we evaluated the active analogs against a panel of drug resistant HBV (Table 2 ). Hepatits B virus is one of the ten leading causes of mortality worldwide, and the emergence of strains resistant to the approved drugs, lamivudine and adefovir dipivoxil, is a major clinical concern (29).
Resistance to lamivudine emerges rapidly during monotherapy and after 4 years affects approximately 70% of treated patients (28) . Adefovir dipivoxil is effective in vitro and in vivo against lamivudine-resistant HBV (40) . We found that like adefovir, HDP-PPen-A retains full activity against the lamivudine-resistant HBV polymerase mutants (L180M, The 50% cytotoxic concentration was determined by neutral red staining as described in Methods. With stationary, confluent HFF cells the assay measures cytotoxicity, but with sparsely plated MRC-5 cells, the assay measures both cell proliferation and cytotoxicity. 
